Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

AHT begins equine herpes virus vaccine research
Equine herpes virus causes respiratory disease, abortion or fatal illness in newborn foals.
Charity to design a modified live virus vaccine 

The Animal Health Trust (AHT) has begun research into developing a new vaccine to protect against equine herpes virus (EHV-1).

Overseen by Dr Neil Bryant, the research comes after the AHT became aware of a pressing need for progress towards a new and improved EHV-1 vaccine.

In March, the Newmarket-based charity was called upon to work with the racing industry and affected parties in dealing with confirmed cases of EHV-1 abortion in Yorkshire and Suffolk. This need led to the development of an Equine Industries EHV Vaccine Steering Group, comprising of world-renowned experts on both human and equine herpes virus.

Chaired by Professor Joe Brownlie of the RVC, the steering group has looked at the existing scientific evidence and agreed the most appropriate way forward is for the AHT to design a modified live virus (MLV) vaccine.

“We’re at the beginning of a very exciting and potentially ground-breaking vaccine development,” said Dr Bryant. “Through our research, we will construct different viruses with attenuating mutations and assess their suitability as MLVs.

“We hope our findings will enable further development by vaccine manufacturers in creating an effective vaccine to protect against the serious clinical signs induced by EHV-1.”

EHV-1 causes respiratory disease, abortion or fatal illness in newborn foals. It also causes neurological disease in adult horses.

Whilst EHV can have severe consequences, there is no vaccine that is licensed to protect against the neurological form of the disease. Existing vaccines do not offer sufficient protection - something that was emphasised in 2016 by the Hertfordshire ‘abortion storm’ in fully vaccinated animals.

“EHV is a major welfare concern for horses and foals and causes emotional, as well as financial strains, on horse owners and breeders around the world,” said Dr Bryant. “It can strike any horse at any time so a vaccine will be of global welfare benefit to all horses, including the Thoroughbred and sports horse breeding industries, and would help control this serious and sometimes fatal disease.”

Become a member or log in to add this story to your CPD history

RCVS Knowledge appoints Veterinary Evidence editor-in-chief

News Story 1
 RCVS Knowledge has welcomed Professor Peter Cockcroft as editor-in-chief for Veterinary Evidence.

A world-renowned expert in evidence-based veterinary medicine, Prof Cockcroft will lead the strategic development and editorial quality of the open-access journal. He was previously in the role from 2017-2020.

Katie Mantell, CEO of RCVS Knowledge, said: "We are excited about the extensive knowledge of evidence-based veterinary medicine and clinical veterinary research that Peter brings, and we look forward to working with him over this next phase of the journal's development." 

Click here for more...
News Shorts
CVS Group hit by cyber attack

CVS Group, which owns more than 450 veterinary practices in the UK, has been hit by a cyber attack.

In a statement, the group said the incident involved unauthorised external access to a limited number of its IT systems. As soon as the attack was discovered, the group took its IT systems temporarily offline, causing 'considerable operational disruption'.

It has warned that the security steps taken and ongoing plans to move its operational systems and IT infrastructure to the Cloud are likely to have an ongoing impact over a number of weeks.

Due to the risk that personal information was accessed, CVS has informed the Information Commissioner's Office. The company is working with third party consultants to investigate the incident.